Literature DB >> 29157749

Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage.

Bradley T Scroggins1, Jeffrey Burkeen1, Ayla O White1, Eun Joo Chung1, Darmood Wei2, Su I Chung1, Luca F Valle1, Shilpa S Patil1, Grace McKay-Corkum1, Kathryn E Hudak1, W Marston Linehan2, Deborah E Citrin3.   

Abstract

PURPOSE: Specificity protein 1 (SP1) is involved in the transcription of several genes implicated in tumor maintenance. We investigated the effects of mithramycin A (MTA), an inhibitor of SP1 DNA binding, on radiation response. METHODS AND MATERIALS: Clonogenic survival after irradiation was assessed in 2 tumor cell lines (A549, UM-UC-3) and 1 human fibroblast line (BJ) after SP1 knockdown or MTA treatment. DNA damage repair was evaluated using γH2AX foci formation, and mitotic catastrophe was assessed using nuclear morphology. Gene expression was evaluated using polymerase chain reaction arrays. In vivo tumor growth delay was used to evaluate the effects of MTA on radiosensitivity.
RESULTS: Targeting of SP1 with small interfering RNA or MTA sensitized A549 and UM-UC-3 to irradiation, with no effect on the BJ radiation response. MTA did not alter γH2AX foci formation after irradiation in tumor cells but did enhance mitotic catastrophe. Treatment with MTA suppressed transcription of genes involved in cell death. MTA administration to mice bearing A549 and UM-UC-3 xenografts enhanced radiation-induced tumor growth delay.
CONCLUSIONS: These results support SP1 as a target for radiation sensitization and confirm MTA as a radiation sensitizer in human tumor models. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29157749      PMCID: PMC5777897          DOI: 10.1016/j.ijrobp.2017.09.049

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  39 in total

1.  Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation.

Authors:  C R Yang; C Wilson-Van Patten; S M Planchon; S M Wuerzberger-Davis; T W Davis; S Cuthill; S Miyamoto; D A Boothman
Journal:  FASEB J       Date:  2000-02       Impact factor: 5.191

2.  MITHRAMYCIN IN THE TREATMENT OF DISSEMINATED TESTICULAR NEOPLASMS.

Authors:  J H BROWN; B J KENNEDY
Journal:  N Engl J Med       Date:  1965-01-21       Impact factor: 91.245

3.  Ionizing radiation stimulates octamer factor DNA binding activity in human carcinoma cells.

Authors:  R L Meighan-Mantha; A T Riegel; S Suy; V Harris; F H Wang; C Lozano; T L Whiteside; U Kasid
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

4.  Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element.

Authors:  D L Ludwig; F Chen; S R Peterson; A Nussenzweig; G C Li; D J Chen
Journal:  Gene       Date:  1997-10-15       Impact factor: 3.688

5.  Epidermal growth factor sensitizes cells to ionizing radiation by down-regulating protein mutated in ataxia-telangiectasia.

Authors:  N Gueven; K E Keating; P Chen; T Fukao; K K Khanna; D Watters; P H Rodemann; M F Lavin
Journal:  J Biol Chem       Date:  2000-11-15       Impact factor: 5.157

Review 6.  Radiation-induced cell death mechanisms.

Authors:  David Eriksson; Torgny Stigbrand
Journal:  Tumour Biol       Date:  2010-05-20

7.  Silencing Egr1 Attenuates Radiation-Induced Apoptosis in Normal Tissues while Killing Cancer Cells and Delaying Tumor Growth.

Authors:  Diana Yi Zhao; Keith M Jacobs; Dennis E Hallahan; Dinesh Thotala
Journal:  Mol Cancer Ther       Date:  2015-07-23       Impact factor: 6.261

8.  A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis.

Authors:  Luz E Núñez; Stephen E Nybo; Javier González-Sabín; María Pérez; Nuria Menéndez; Alfredo F Braña; Khaled A Shaaban; Min He; Francisco Morís; José A Salas; Jürgen Rohr; Carmen Méndez
Journal:  J Med Chem       Date:  2012-06-07       Impact factor: 7.446

9.  Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.

Authors:  S W Blume; R C Snyder; R Ray; S Thomas; C A Koller; D M Miller
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue.

Authors:  Carolina Vizcaíno; Luz-Elena Núñez; Francisco Morís; José Portugal
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

View more
  1 in total

1.  Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model.

Authors:  Rinku Dutta; Roukiah Khalil; Karthick Mayilsamy; Ryan Green; Mark Howell; Srinivas Bharadwaj; Shyam S Mohapatra; Subhra Mohapatra
Journal:  Front Immunol       Date:  2021-07-26       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.